Related Experiment Video
Updated: Aug 17, 2025
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
Ghrelin system in Alzheimer's disease
Jing Tian1, Tienju Wang1, Heng Du2
1Department of Pharmacology and Toxicology, University of Kansas, KS, USA.
Current Opinion in Neurobiology
|December 17, 2022
Summary
Ghrelin system deregulation may contribute to Alzheimer's disease (AD) pathology. Targeting ghrelin signaling offers potential therapeutic strategies for this common neurodegenerative disorder in seniors.
Area of Science:
- Neuroscience
- Endocrinology
- Gerontology
Background:
- Alzheimer's disease (AD) is the leading cause of dementia in older adults.
- Systemic factors are increasingly implicated in AD pathogenesis.
- Ghrelin, a brain-gut peptide, and its signaling pathway (GOAT/GHSR) are recognized for neurotropic effects.
Purpose of the Study:
- To review recent research on ghrelin signaling dysregulation in AD.
- To explore the contribution of ghrelin system to AD brain pathology.
- To discuss therapeutic strategies targeting ghrelin signaling for AD treatment.
Main Methods:
- Literature review of recent studies on ghrelin signaling and AD.
- Analysis of mechanisms linking ghrelin pathway to AD neuropathology.
- Evaluation of potential therapeutic interventions targeting the ghrelin system.
Main Results:
- Ghrelin signaling dysregulation is increasingly linked to the development of AD.
- Mechanisms of ghrelin's contribution to AD brain pathology are being elucidated.
- Targeting ghrelin signaling presents a promising avenue for AD therapeutics.
Conclusions:
- Ghrelin system dysregulation plays a role in Alzheimer's disease.
- Further research into ghrelin signaling mechanisms is crucial for understanding AD.
- Therapeutic targeting of the ghrelin pathway holds potential for treating Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
608
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
608
01:22Alzheimer's Disease: Treatment
240
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
240
01:30Regulation of Food Intake
314
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
314
01:37Neural Regulation
39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
01:24Glucagon-like Receptor Agonists
383
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
01:00Enzyme-linked Receptors
79.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.3K